All-cause health care utilization and costs associated with newly diagnosed multiple sclerosis in the United States

Journal of Managed Care Pharmacy

Volumn 16, Issue 9, 2010, Pages 703-712

  Asche, Carl V ^a   Singer, Mendel E ^b   Jhaveri, Mehul ^c   Chung, Hsingwen ^d   Miller, Aaron ^e  

^a UNIVERSITY OF UTAH   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SANOFI   (France)

^d RUTGERS UNIVERSITY   (United States)

^e MAIMONIDES MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; NATALIZUMAB; NEUROLEPTIC AGENT;

ADULT; ARTICLE; CHI SQUARE TEST; COHORT ANALYSIS; COMORBIDITY; DATA BASE; EMERGENCY WARD; EMPLOYEE; FEMALE; GENDER; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HEALTH SERVICE; HOSPITAL PATIENT; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; MULTIPLE SCLEROSIS; OCCUPATIONAL THERAPY; OUTPATIENT; PHARMACY; PHYSICIAN; PHYSIOTHERAPY; QUALITATIVE ANALYSIS; RADIOLOGY; RETROSPECTIVE STUDY; SPEECH THERAPY; STUDENT T TEST; UNITED STATES;

EID: 78649495042     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2010.16.9.703     Document Type: Article

References (19)

1. Keegan BM, Noseworthy JH. Multiple sclerosis. Annu Rev Med. 2002;53:285-302.
2. U.S. Food and Drug Administration. First monoclonal antibody treatment for multiple sclerosis approved. P04-107, November 23, 2004. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2004/ucm108380.htm. Accessed October 7, 2010.
3. National Multiple Sclerosis Society: Who Gets MS? Available at: http://www.nationalmssociety.org/about-multiple-sclerosis/what-we-know-about-ms/who-gets-ms/index.aspx. Accessed October 7, 2010.
4. National Institute of Neurological Disorders and Stroke, National Institutes of Health. Multiple sclerosis: hope through research. July 1, 2010. Available at: http://www.ninds.nih.gov/disorders/multiple_sclerosis/detail_multiple_sclerosis.htm#158973215. Accessed October 7, 2010.
5. National Collaborating Centre for Chronic Conditions, National Institute for Health and Clinical Excellence. Multiple sclerosis: national clinical guideline for diagnosis and management in primary and secondary care. 2004. Available at: http://www.nice.org.uk/nicemedia/live/10930/46699/46699.pdf. Accessed October 7, 2010.
6. Henriksson F, Fredrikson S, Masterman T, Jönsson B. Costs, quality of life and disease severity in multiple sclerosis: a cross-sectional study in Sweden. Eur J Neurol. 2001;8(1):27-35.
7. Kobelt G, Berg J, Atherly D, Hadjimichael O. Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States. Neurology. 2006;66(11):1696-702.
8. Bennet R, Cisternas M, Foreman A, Meletiche D, Miller D, Al-Sabbagh A. Impact of relapses on total costs of care for patients with multiple sclerosis. PND12. Poster presented at: 2007 International Society for Pharmacoeconomics and Outcomes Research 12th Annual International Meeting; May 19-23, 2007; Arlington, VA.
9. Patwardhan MB, Matchar DB, Samsa GP, McCrory DC, Williams RG, Li TT. Cost of multiple sclerosis by level of disability: a review of the literature. Mult Scler. 2005;11(2):232-39.
10. Sobocki P, Pugliatti M, Lauer K, Kobelt G. Estimation of the cost of MS in Europe: extrapolations from a multinational cost study. Mult Scler. 2007;13(8):1054-64.
11. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47(11):1245-51.
12. Red Book: Pharmacy's Fundamental Reference, 2008 Edition. Montvale, NJ: Thomson Healthcare; 2008.
13. Prescott JD, Factor S, Pill M, Levi GW. Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database. J Manag Care Pharm. 2007;13(1):44-52. Available at: http://amcp.org/data/jmcp/44-52.pdf.
14. Pope GC, Urato CJ, Kulas ED, Kronick R, Gilmer T. Prevalence, expenditures, utilization, and payment for persons with MS in insured populations. Neurology. 2002;58(1):37-43.
15. O'Brien JA, Ward AJ, Patrick AR, Caro J. Cost of managing an episode of relapse in multiple sclerosis in the United States. BMC Health Serv Res. 2003;3(1):17. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC201004/pdf/1472-6963-3-17.pdf. Accessed October 7, 2010.
16. Ozminkowski RJ, Marder WD, Hawkins K, et al. The use of diseasemodifying new drugs for multiple sclerosis treatment in private-sector health plans. Clin Ther. 2004;26(8):1341-54.
17. Minden S, Hoaglin D, Jureidini S, et al. Disease-modifying agents in the Sonya Slifka Longitudinal Multiple Sclerosis Study. Mult Scler. 2008;14(5):640-55.
18. Vollmer TL, Hadjimichael O, Preiningerova J, Ni W, Buenconsejo J. Disability and treatment patterns of multiple sclerosis patients in United States: a comparison of veterans and non-veterans. J Rehabil Res Dev. 2002;39(2):163-74.
19. Lo AC, Hadjimichael O, Vollmer TL. Treatment patterns of multiple sclerosis patients: a comparison of veterans and non-veterans using the NARCOMS registry. Mult Scler. 2005;11(1):33-40.